Regulation Effect of Syndrome Differentiation and Treatment of Bawei Shenqi Wan Combined with Bazhengsan in Patients with Recurrent Urinary Tract Infection and Old Age

YAN Xu-dong; HUANG Chao; YANG Ling

doi:10.13422/j.cnki.syfjx.20181736

您当前的位置：

首页 >

文章列表页 >

Regulation Effect of Syndrome Differentiation and Treatment of Bawei Shenqi Wan Combined with Bazhengsan in Patients with Recurrent Urinary Tract Infection and Old Age

更新时间：2024-01-04

- Regulation Effect of Syndrome Differentiation and Treatment of Bawei Shenqi Wan Combined with Bazhengsan in Patients with Recurrent Urinary Tract Infection and Old Age
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 24, Issue 17, Pages: 195-200(2018)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20181736
  CLC： R277.5
- Published：2018
- 稿件说明：
移动端阅览
YAN Xu-dong, HUANG Chao, YANG Ling. Regulation Effect of Syndrome Differentiation and Treatment of Bawei Shenqi Wan Combined with Bazhengsan in Patients with Recurrent Urinary Tract Infection and Old Age[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(17): 195-200.
DOI：

YAN Xu-dong, HUANG Chao, YANG Ling. Regulation Effect of Syndrome Differentiation and Treatment of Bawei Shenqi Wan Combined with Bazhengsan in Patients with Recurrent Urinary Tract Infection and Old Age[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(17): 195-200. DOI： 10.13422/j.cnki.syfjx.20181736.

摘要

目的：观察八味肾气丸合八正散加减治疗中老年反复发作性尿路感染（RUTI）的临床疗效及对免疫功能和炎症因子的影响。方法：将140例患者，按区组随机分为观察组和对照组各70例。对照组口服盐酸左氧氟沙星片，0.2 g/次，2次/d。连续治疗2周，尿培养阴性后采用头孢氨苄甲氧苄啶胶囊，0.25 g·d-1，睡前服用。观察组在对照组治疗的基础上加用八味肾气丸合八正散加减内服，1剂/d。两组疗程均连续治疗12周。进行治疗前后主要临床症状和生活质量评分；记录6个月内的复发情况；检测治疗前后α1-微球蛋白（α1-MG）和β2-微球蛋白（β2-MG），尿N-乙酰-β-氨基葡萄糖苷酶（NAG）水平；检测治疗前后T细胞亚群（CD3+，CD4+，CD8+，CD4+/CD8+）和尿液分泌型免疫球蛋白A（SIgA）水平；检测治疗前后肿瘤坏死因子-α（TNF-α），白细胞介素-6（IL-6），IL-8和降钙素原（PCT）等炎症因子水平。结果：经秩和检验，观察组患者临床疗效优于对照组（P<0.05）；观察组各症状评分和总分均低于对照组（P<0.01）；治疗后观察组α1-MG，β2-MG和NAG水平均低于对照组（P<0.01）；观察组CD4+，CD4+/CD8+和SIgA均高于对照组（P<0.05），CD8+低于对照组（P<0.05）；观察组TNF-α，IL-6，IL-8和PCT水平均低于对照组（P<0.01）；观察组患者生理职能、活力、情感职能和精神健康4个维度评分均高于对照组（P<0.05）；观察组在6个月随访中平均复发次数少于对照组（P<0.01），观察组复发率为37.74%，低于对照组的60.98%（χ2=5.003，P<0.05）。结论：八味肾气丸合八正散加减治疗肾虚湿热型RUTI中老年患者可减轻临床症状、减少复发，提高生活质量，保护肾功能，并具有调节免疫和抗炎效应，近期和远期疗效均优于单纯西医治疗。

Abstract

Objective:To observe the clinical efficacy of syndrome differentiation and treatment of Bawei Shenqi Wan combined with Bazhengsan to recurrent urinary tract infections (RUTI) in the middle and old age

and investigate its effects on immunity and inflammatory factors. Method:One hundred and forty eligible patients were randomly divided into control group (70 cases) and observation group (70 cases) by using SAS software. Patients in the control group got levofloxacin tablets by oral administration

0.2 g/time

2 times/days

for continuous 2 weeks. And cefalexin and trimethoprim capsules were given at 0.25 g/day when urine culture showed negative results. Based on the treatment in control group

the patients in observation group additionally got Bawei Shenqi Wan combined with Bazhengsan

1 dose/day. The treatment course was 12 weeks in both groups. Before and after treatment

scores of the main symptoms and quality of life were graded. Relapse within 6 months was recorded. And the levels of α1-microglobulin (α1-MG) and β2-microglobulin (β2-MG)

N-acetyl-β-D-glucosaminidase (NAG)

T cell subgroup (CD3+

CD4+

CD8+

CD4+/CD8+)

urine secretory immunoglobulin A (SIgA)

tumor necrosis factor-α (TNF-α)

interleukin (IL-6) and calcitonin (PCT) were detected. Result:As analyzed by rank sum test

the clinical efficacy in observation group was superior to that in the control group (P<0.05). Scores of symptoms and the total score were all lower than those in control group (P<0.01). After treatment

levels of α1-MG

β2-MG

NAG

TNF-α

IL-6

IL-8 and PCT were all lower than those in control group (P<0.01). Levels of CD4+

CD4+/CD8+and SIgA in the observation group were higher than those in the control group (P<0.05)

while level of CD8+ was lower than that in the control group (P<0.05). The scores of physiological function

vitality

emotional function and mental health in the observation group were higher than those in the control group (P<0.05). The average number of recurrence times was less than that in the control group during the 6 months' follow-up (P<0.01)

and the recurrence rate in observation group was 37.74%

lower than 60.98% in control group (χ2=5.003

P<0.05). Conclusion:Bawei Shenqi Wan combined with Bazhengsan in the treatment of recurrent urinary tract infections in the middle and old age can relieve clinical symptoms and reduce recurrence rate

improve quality of life

protect renal function and can regulate immunity and anti-inflammatory function

superior to pure western medicine in short and long-term effects.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical Efficacy of Early Application of Da Xianxiongtang in Mitigating Progression of Acute Pancreatitis

Efficacy of Shexiang Tongxin Dropping Pills in Treatment of Coronary Slow Flow and Its Effect on Inflammatory Factors

Effect of Zishen Tongguan Formula on "Gut-prostate" Axis of Rats with Chronic Non-bacterial Prostatitis Based on 16S rDNA Sequencing

Effect of Rhei Radix et Rhizoma Before and After Steaming with Wine on Intestinal Flora and Immune Environment in Constipation Model Mice

Exploring Mechanism of Different Processed Products of Baiyaojian and Its Formula in Treating Ulcerative Colitis Based on Serum Metabolomics and Flow Cytometry

Related Author

REN Dongsheng

TAN Judan

LIAO Haitang

LIU Qinghai

WENG Xiangwen

GUO Wenhui

WANG Yiyan

ZHOU Yuling

Related Institution

Chengdu University of Traditional Chinese Medicine（TCM）

Chongqing TCM Hospital

Hospital of Chengdu University of TCM

Dongzhimen Hospital， Beijing University of Chinese Medicine

Jiangsu Engineering Research Centre for Innovative Chinese Medicine Preparations， Jiangsu Integration Innovation Centre for Specialty Chinese Medicine Preparations，Affiliated Hospital of Nanjing University of Chinese Medicine/Jiangsu Province Hospital of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰